The 7-year itch? Boehringer culls $600M cancer pact with CureVac, heaping more woe to the biotech

Back in 2014, a German pharma and a then largely unknown fellow German biotech in CureVac penned a $600 million mRNA cancer pact.

Seven years down the line, that’s been axed, leading to searching questions about CureVac’s future after it failed to match the efficacy of rival mRNA COVID vaccines.

Buried in its financials posted Monday morning, CureVac quietly reported that Boehringer Ingelheim has walked away from the deal, which was penned in 2014 and included $45 million upfront plus $556 million in biobucks.